FGF21 gene therapy as treatment for obesity and insulin resistance

Abstract Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic ag...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Veronica Jimenez, Claudia Jambrina, Estefania Casana, Victor Sacristan, Sergio Muñoz, Sara Darriba, Jordi Rodó, Cristina Mallol, Miquel Garcia, Xavier León, Sara Marcó, Albert Ribera, Ivet Elias, Alba Casellas, Ignasi Grass, Gemma Elias, Tura Ferré, Sandra Motas, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Virginia Haurigot, Jesus Ruberte, Fatima Bosch
Format:	Artigo
Sprog:	Inglês
Udgivet:	Springer Nature 2018-07-01
Serier:	EMBO Molecular Medicine
Fag:	AAV gene therapy FGF21 insulin resistance obesity type 2 diabetes
Online adgang:	https://doi.org/10.15252/emmm.201708791
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!